The article presents the result NEODOLEX study. It was Russian multicenter statistical efficacy and tolerability observation of Neodolpasse which is a fixed combination of the non-steroidal anti-inflammatory drug (NSAID) diclofennac (75 mg) and the muscle relaxant orphenadrine (30 mg) for acute nonspecific back pain and radiculopathy treatment. The study has showed Neodolpasse infusions lead to the fast (after 24 hours) and significant pain regression (more than 50%) in 94% of patients. Depending on the frequency of Neodolpasse use, additional application of other analgesics was required in 21—35% of patients with acute nonspecific back pain and 11—17% of patients with radiculopathy. © 2022, Media Sphera Publishing Group. All rights reserved.